Donidalorsen Treatment in Children With Hereditary Angioedema
Status:
NOT_YET_RECRUITING
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).